Clinical trialPhase 1Recruiting
Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
MYE Symphony: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Recruiting
- Study type
- Interventional
- Start
- 2 August 2023
- Expected end
- 31 August 2028
- Enrollment
- 48 participants
- Sites
- 6
- Primary outcomes
- To evaluate the safety and tolerability of MT-302 through incidence of Adverse Events; To establish the maximum tolerated dose (MTD)
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 18 January 2024
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.
Detailed description public domain (ClinicalTrials.gov)
The study has 4 Cohorts. Each Cohort has 4 Cycles. For Cohorts 1-3, the dosing regimen will be every 14 days for 3 doses, followed by administration once every 28 days for three doses. For Cohort 4, the dosing regimen will be modified. Participants will receive one dose of MT-302 every week for 3 doses, followed by administration once every 28 days for three additional doses. A Safety Review Committee (SRC) will provide oversight for this study. The primary responsibility of the SRC is to safeguard study participants by reviewing and assessing the clinical safety data being collected during the conduct of the study.
Intervention public domain (ClinicalTrials.gov)
Drug: MT-302 (A). MT-302 is an investigational drug
Arm public domain (ClinicalTrials.gov)
A (MT-302) (experimental): Participants will receive MT-302 through intravenous infusion.
Primary outcome public domain (ClinicalTrials.gov)
To evaluate the safety and tolerability of MT-302 through incidence of Adverse Events. Adverse Events will be graded according to the NCI-CTCAE, version 5.0 Time frame: Up to Week 20.
Primary outcome public domain (ClinicalTrials.gov)
To establish the maximum tolerated dose (MTD). based on dose limiting toxicities (DLTs) and the recommended Phase 2 dose (RP2D) Time frame: Up to Week 20.
Secondary outcome public domain (ClinicalTrials.gov)
To further characterize the safety of MT-302 through incidence of Adverse Events. Time frame: Up to Week 20.
Secondary outcome public domain (ClinicalTrials.gov)
To assess the pharmacokinetics (PK) of MT-302. Time frame: Up to Week 20.
Secondary outcome public domain (ClinicalTrials.gov)
To assess the pharmacokinetics (PK) of MT-302. Time frame: Up to Week 20.
Secondary outcome public domain (ClinicalTrials.gov)
To assess the pharmacokinetics (PK) of MT-302. Time frame: Up to Week 20.
Secondary outcome public domain (ClinicalTrials.gov)
To assess the pharmacokinetics (PK) of MT-302. Time frame: Up to Week 20.
Secondary outcome public domain (ClinicalTrials.gov)
To assess the pharmacokinetics (PK) of MT-302. Time frame: Up to Week 20.
Eligibility public domain (ClinicalTrials.gov)
Inclusion Criteria: 1. Adults age ≥ 18 inclusive at the time the Informed Consent Form (ICF) is signed. 2. Histologically proven, metastatic or advanced epithelial cancer including the following cancer types: 1. Urothelial 2. Cervical 3. Ovarian epithelial 4. Triple-negative breast 5. HR+/HER2- breast 6. Pancreatic ductal adenocarcinoma 7. Gastric adenocarcinoma 8. Esophageal carcinoma 9. Non-small cell lung 10. Colorectal 3. Progressive disease at baseline, refractory or relapsed to standard of care or who have declined standard therapy. 4. Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria v 1.1. 5. Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1. 6. Life expectancy of \> 12 weeks. 7. Echocardiogram (ECHO) or multiple gated acquisition scan showing an ejection fraction greater than or equal to 50%. 8. Electrocardiogram (ECG) showing no clinically significant abnormality at Screening or showing an average QTc interval \< 450 msec in males and \< 470 msec in females (\< 480 msec for participants with bundle branch block). Either Fridericia's or Bazett's formula may be used to correct the QT interval. 9. Oxygen saturation of greater than or equal to 90% on room air measured by pulse oximetry. 10. Adequate organ function as defined by laboratory values at Screening. 11. Willing and able to provide written informed consent. 12. Willing to perform and comply with all study procedures including undergoing study-related biopsies and attending clinic visits as scheduled. 13. Men must abstain from sperm donation during study treatment or for 4 months following last dose of study treatment. 14. Men and WOCBP must be willing to practice a highly effective method of contraception. Exclusion Criteria: 1. Known active CNS metastasis and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, (ie, without evidence of progression for at least 4 weeks by repeat imaging), clinically stable, and without requirement of steroid treatment for at least 14 days prior to the first dose of study intervention. 2. Pregnant or nursing women. 3. Must be \> 28 days beyond major surgery, including hepatectomy or joint replacement. 4. Prior allogeneic bone marrow transplantation or solid organ transplant. 5. Spinal cord compression not definitively treated with surgery and/or radiation. 6. Uncontrolled pleural effusion, pericardial …
Enrollment public domain (ClinicalTrials.gov)
Enrollment: 48 participants (estimated).